Investment Analysts’ Updated EPS Estimates for August, 14th (AZN, IMI, MLCO, MVC, NGM, NHI, NMFC, NR, OESX, ONCE)

Share on StockTwits

Investment Analysts’ updated eps estimates for Wednesday, August 14th:

AstraZeneca (LON:AZN) had its sell rating reissued by analysts at UBS Group AG. They currently have a GBX 5,700 ($74.48) target price on the stock, up from their previous target price of GBX 5,400 ($70.56).

IMI (LON:IMI) had its neutral rating reiterated by analysts at UBS Group AG. UBS Group AG currently has a GBX 1,010 ($13.20) price target on the stock, down from their previous price target of GBX 1,050 ($13.72).

Melco Resorts & Entertainment (NASDAQ:MLCO) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Melco Resorts & Entertainment Ltd is a developer, owner and operator of casino gaming and entertainment casino resort facilities primarily in Asia. Melco Resorts & Entertainment Ltd, formerly known as Melco Crown Entertainment Limited, is based in Hong Kong. “

MVC Capital (NYSE:MVC) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “MVC CAPITAL INC is a business development company traded on the New York Stock Exchange, under the listing symbol MVC and is advised by The Tokarz Group Advisers LLC. MVC provides long-term equity and debt investment capital to fund growth, acquisitions and recapitalizations of small and middle-market companies in a variety of industries primarily located in the U.S. The investments can take the form of common and preferred stock (control and non-control investments) and warrants or rights to acquire equity interests; senior and subordinated loans; or convertible securities. MVC serves as the lead investor for transactions, as well as a co-investor in companies along with other private equity sponsors. “

NGM Biopharmaceuticals (NYSE:NGM) had its buy rating reaffirmed by analysts at Stifel Nicolaus. Stifel Nicolaus currently has a $26.00 price target on the stock. The analysts wrote, “We are reiterating our Buy rating and $26 target price after NGM reported its 2Q19 financials and business update. We remain positively biased ahead of NGM282’s (aldafermin) Phase 2 cohort 4 interim data expected in 4Q19 (non-invasive biomarkers), but more importantly, aldafermin’s top line results in early 2020 where we believe it has the potential to demonstrate a histological fibrosis benefit in NASH patients in as little as 24 weeks of treatment. The latter remains the key catalyst for the stock, in our view. In the press release, NGM indicated it had completed enrollment for cohort 4 and management also highlighted pipeline progress for some of its earlier stage programs including for NGM621, which is being developed for geographic atrophy, and NGM120 for CACS.””

National Health Investors (NYSE:NHI) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “National Health Investors, Inc. is a real estate investment trust which invests in income producing health care properties primarily in the long-term care industry. The company provides current income for distribution to stockholders through investments in health care related facilities, including long-term care facilities, acute care hospitals, medical office buildings, retirement centers and assisted living facilities. “

New Mountain Finance (NYSE:NMFC) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “New Mountain Finance Corporation is a Business Development Company specializing in investments in middle market companies and debt securities at various levels of the capital structure, including first and second lien debt, unsecured notes, bonds, and mezzanine securities. It invests in various industries that include software, education, business services, distribution and logistics, federal services, healthcare services and products, healthcare facilities, energy, media, consumer and industrial services, healthcare Information Technology, Information Technology and services, specialty chemicals and materials, telecommunication, retail, and power generation. It seeks to invest in United States. The Company’s investment objective is to generate current income and capital appreciation through the sourcing and origination of debt securities at all levels of the capital structure, including first and second lien debt, notes, bonds and mezzanine securities. “

Newpark Resources (NYSE:NR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Newpark Resources, Inc. is a worldwide provider of value-added drilling fluids systems, and composite matting systems used in oilfield and other commercial markets. “

Orion Energy Systems (NASDAQ:OESX) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ORION ENERGY SYSTEMS, INC. is a leading power technology enterprise that designs, manufactures and implements energy management systems, consisting primarily of high-performance, energy efficient lighting systems, controls and related services, for commercial and industrial customers without compromising their quantity or quality of light. “

Spark Therapeutics (NASDAQ:ONCE) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Spark Therapeutics, Inc. offers gene therapy. The Company’s product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. “

Oxford Instruments (OTCMKTS:OXINF) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Oxford Instruments plc is a holding company, which engages in the research, development, manufacture and sale of high technology tools and systems. Its operating segment includes Nanotechnology Tools, Industrial Products and Service. Nanotechnology Tools segment includes high technology tools to characterize, analyze, manipulate and fabricate at a nano scale. Industrial Products segment develops and manufactures tools and components for industrial applications. Service segment deals with knowledgeable support services, training and refurbishment. Oxford Instruments plc is headquartered in Abingdon, the United Kingdom. “

Oxford Industries (NYSE:OXM) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Oxford Industries, Inc. is an apparel company which designs, sources, markets and distributes products bearing the trademarks of its owned and licensed brands. Oxford’s owned brands include Tommy Bahama®, Lilly Pulitzer®, Oxford Golf®, and Billy London®. The Company operates retail stores, internet websites and restaurants. The Company has granted licenses to select third parties to produce and sell certain product categories under its Tommy Bahama and Lilly Pulitzer brands. The Company also holds exclusive licenses to produce and sell certain product categories under the Kenneth Cole®, Geoffrey Beene®, and Dockers® labels. Oxford’s wholesale customers include department stores, specialty stores, national chains, warehouse clubs, and Internet retailers. “

Tp Icap (LON:TCAP) had its buy rating reiterated by analysts at Peel Hunt.

TUI (LON:TUI) had its sell rating reissued by analysts at UBS Group AG.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Downgrades Dunkin Brands Group  to Hold
Zacks Investment Research Downgrades Dunkin Brands Group to Hold
Esperion Therapeutics  Given New $70.00 Price Target at Stifel Nicolaus
Esperion Therapeutics Given New $70.00 Price Target at Stifel Nicolaus
Zacks Investment Research Upgrades First Community  to Hold
Zacks Investment Research Upgrades First Community to Hold
ConnectOne Bancorp  Stock Rating Upgraded by Zacks Investment Research
ConnectOne Bancorp Stock Rating Upgraded by Zacks Investment Research
ValuEngine Lowers Cue Biopharma  to Hold
ValuEngine Lowers Cue Biopharma to Hold
Chimerix  Upgraded by Zacks Investment Research to Hold
Chimerix Upgraded by Zacks Investment Research to Hold


© 2006-2019 Ticker Report